Therefore, targeting the SLC7A11‐AS1/SLC7A11 pair to reduce intracellular GSH levels and promote cancer cell sensitivity to anticancer drugs may represent a promising therapeutic strategy in cancer treatment. Here, SLC7A11 is linked to cancer.